Viewing Study NCT00042003


Ignite Creation Date: 2025-12-24 @ 7:32 PM
Ignite Modification Date: 2025-12-30 @ 8:23 PM
Study NCT ID: NCT00042003
Status: COMPLETED
Last Update Posted: 2024-08-02
First Post: 2002-07-19
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
Sponsor: Astex Pharmaceuticals, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Eligibility Module Contacts Locations Module